Moderna recently announced that they are making changes in their new vaccine production. The news of Moderna upgrades vaccine comes after the quest of fighting against new virus variants. As of now, the UK and South African virus variants have been detected. But the virus is mutating, and health experts need to improve vaccines constantly.
Moderna upgrades vaccine
The upgraded version of vaccines will protect us against different strains of the virus. In all probability, the coronavirus vaccine dosage will come with a booster shot to protect.
Health experts across the globe are struggling to combat the effects of a mutating coronavirus. The original virus killed over 2 million globally and continues to change and impact our lives.
Stéphane Bancel, the CEO of Moderna, recently gave a statement acknowledging the coronavirus’s impacts due to the pandemic. He then said it is imperative to protect people from the evolving virus strains as well.
Moderna went through trials to prove that their existing vaccine is already effective against the UK variant of coronavirus. However, the vaccine was six-folds less protective against the strains from South Africa. When one takes the vaccine after being infected from the South African variant, the level of antibody production reduces by six-folds.
Even if with such a high drop, Moderna plans to neutralize antibodies. The process will bind to viruses and eventually block them from getting into the cells. Thus, one will still have protection from the virus. Bancel said that they do not know how the impact will remain in the following six to 12 months.
Studies by Moderna
Bancel states that the Moderna vaccine upgrades will adhere to complete caution. However, the example of the South African potent virus suggests that one might not have complete protection for future mutations of the virus. Moreover, one’s immunity can go down with time.
The study done by Moderna was in association with Vaccine Research Center at National Institute of Allergy and Infectious Diseases. They studied blood samples from monkeys who were immunized against eight people who got the normal two-doses of vaccines. The results have not been published as yet, neither has it been peer-reviewed.
The Moderna CEO also said that the ongoing research is crucial, but they aim to provide immunity against emerging strains. He also said that they could not lag and let the new variants overpower.